Historically, optic nerve involvement has been excluded from MS diagnostic criteria, but its inclusion in the new iteration ...

Compounded GLP-1s are still accessible on telehealth sites, despite an agreement with Eli Lilly to cease copycat sales.

If Eli Lilly presents strong data, the stock could be set to rally and potentially be on a path to reaching new highs. Should ...

Eli Lilly (LLY) revealed a new stipulation regarding its business dealings with telehealth companies Ro and LifeMD (LFMD), ...

Eli Lilly is beefing up muscle health R&D, partnering with Juvena Therapeutics in a deal that includes an upfront fee and ...

Labour Court says SIPTU should be recognised to represent Eli Lilly workers in Cork amid a growing industrial standoff ...

Madison Investments, an investment advisor, released its “Madison Sustainable Equity Strategy” first quarter 2025 investor ...

Companies are always in the race for the top spot, and the only way to achieve it is by reaching a high market valuation. The ...

The deal is Lilly’s second obesity tie-up in a week, after sinking up to $870 million into an agreement with Camurus to ...

Eli Lilly & Co. will only work with telehealth firms that agree to stop selling copycat versions of weight-loss drugs, ...

Eli Lilly and Company thrives on its groundbreaking weight-loss drug tirzepatide. Learn why we could see a $50B market and ...

Eli Lilly lands an $870 million pact with Camurus to build long-acting obesity treatments, tapping FluidCrystalslow-release ...